Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (5): 825-832. doi: 10.19723/j.issn.1671-167X.2023.05.008

Previous Articles     Next Articles

Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus

Dong LAN1,2,Zhuo LIU1,Yu-xuan LI1,Guo-liang WANG1,Xiao-jun TIAN1,Lu-lin MA1,Shu-dong ZHANG1,Hong-xian ZHANG1,*()   

  1. 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Urology, Guang'an People's Hospital, Guang'an 638500, Sichuan, China
  • Received:2023-03-25 Online:2023-10-18 Published:2023-10-09
  • Contact: Hong-xian ZHANG E-mail:zwl2006@163.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate and analyze the risk factors of massive hemorrhage in patients with renal cell carcinoma and venous tumor thrombus undergoing radical nephrectomy and removal of venous tumor thrombus. Methods: From January 2014 to June 2020, 241 patients with renal cancer and tumor thrombus in a single center of urology at Peking University Third Hospital were retrospectively analyzed. All patients underwent radical nephrectomy and removal of venous tumor thrombus. The relevant preoperative indicators, intraoperative conditions, and postoperative data were statistically analyzed by using statistical software of SPSS 18.0. The main end point of the study was intraoperative bleeding volume greater than 2 000 mL. Logistic regression analysis was used to determine the relevant influencing factors. First, single factor Logistic regression was used for preliminary screening of influencing factors, and variables with single factor Logistic regression analysis P < 0.05 were included in multivariate Logistic regression. In all statistical analyses, P < 0.05 is considered statistically significant. Results: Among the 241 patients included, there were 60 cases of massive hemorrhage, 48 males and 12 females, with a median age of 62 years. The number of non-massive hemorrhage was 181. There were 136 males and 45 females, with a median age of 59 years. Univariate analysis showed that the clinical symptoms (both systemic and local symptoms, OR 2.794, 95%CI 1.087-7.181, P=0.033), surgical approach (open surgery, OR 9.365, 95%CI 4.447-19.72, P < 0.001), Mayo grade (Mayo 3-4, OR 5.257, 95%CI 2.806-10.886, P < 0.001), American Society of Anesthesiologists (ASA) score (ASA level 3, OR 2.842, 95%CI 1.338-6.036, P=0.007), preoperative hemoglobin (OR 0.978, 95%CI 0.965-0.991, P=0.001), preoperative platelet count (OR 0.996, 95%CI 0.992-1.000, P=0.037), maximum tumor thrombus width (OR 1.061, 95%CI 1.033-1.091, P < 0.001), Complicated with bland thrombus (OR 4.493, 95%CI 2.264-8.915, P < 0.001), adrenalectomy (OR 3.101, 95%CI 1.614-5.958, P=0.001), segmental resection of the inferior vena cava (OR 2.857, 95%CI 1.395-5.852, P=0.004). There was a statistically significant difference in these aspects(P < 0.05). Multivariate Logistic regression analysis showed that there was a statistically significant difference in surgical approach (open surgery, OR 6.730, 95%CI 2.947-15.368;P < 0.001), Mayo grade (Mayo 3-4, OR 2.294, 95%CI 1.064-4.948, P=0.034), Complicated with bland thrombus (OR 3.236, 95%CI 1.492-7.020, P=0.003). Conclusion: Combining the results of univariate and multivariate Logistic regression analysis, the surgical approach, Mayo grade, and tumor thrombus combined with conventional thrombus were associated risk factors for massive hemorrhage during surgery for renal cell carcinoma with tumor thrombus. Patients who undergo open surgery, high Mayo grade, and tumor thrombus combined with conventional thrombus are at a relatively higher risk of massive hemorrhage.

Key words: Renal cell carcinoma, Venous tumor thrombus, Hemorrhage

CLC Number: 

  • R737.1

Table 1

Comparison of clinicopathological characteristics between massive hemorrhage group and non-massive hemorrhage group"

Items Non-massive hemorrhage group (n=181) Massive hemorrhage group (n=60) P
Gender, n (%) 0.488
  Male 136 (75.1) 48 (80.0)
  Female 45 (24.9) 12 (20.0)
Age/years, M (P25, P75) 59 (53, 66) 62 (54, 68) 0.122
Clinical symptoms, n (%) 0.175
  None 44 (24.3) 9 (15.0)
  Local symptoms 93 (51.4) 31 (51.7)
  Systematic symptoms 16 (8.8) 4 (6.7)
  Both 28 (15.5) 16 (26.7)
BMI/(kg/m2), M (P25, P75) 23.3 (21.1, 25.8) 24.3 (21.4, 26.1) 0.107
Surgical approach, n (%) < 0.001*
  Laparoscopic surgery 118 (65.2) 10 (16.7)
  Open 63 (34.8) 50 (83.3)
Mayo classification, n (%) < 0.001*
  0 56 (30.9) 4 (6.7)
  1 40 (22.1) 2 (3.3)
  2 63 (34.8) 28 (46.7)
  3 16 (8.9) 11 (18.3)
  4 6 (3.3) 15 (25.0)
ASA grade, n (%) 0.001*
  1 16 (8.8) 0 (0)
  2 146 (80.7) 45 (75.0)
  3 19 (10.5) 15 (25.0)
Preoperative serum creatinine/(μmol/L), 91 (80.5, 107) 93 (81, 112) 0.431
M (P25, P75)
Preoperative hemoglobin/(g/L), M (P25, P75) 124 (109.5, 139.5) 113 (97, 125) ＜0.001*
Preoperative neutrophil/(×109/L), M (P25, P75) 4.5 (3.4, 5.5) 4.4 (3.7, 5.1) 0.754
Preoperative lymphocyte/(×109/L), M (P25, P75) 1.3 (1.0, 1.6) 1.2 (0.9, 1.5) 0.043*
Preoperative monocyte/(×109/L), M (P25, P75) 0.4 (0.3, 0.5) 0.4 (0.3, 0.5) 0.422
Preoperative platelet/(×109/L), M (P25, P75) 241 (189.0, 303.5) 213 (167.0, 291.0) 0.033*
Lesion side, n (%) 0.646
  Left 66 (36.5) 24 (40.0)
  Right 115 (63.5) 36 (60.0)
Tumor diameter/cm, M (P25, P75) 8.8 (6.7, 10.5) 8.7 (6.8, 10.9) 0.786
Maximum tumor thrombus width/mm, M (P25, P75) 20 (15, 30) 30 (20, 35) ＜0.001*
Clinical phase of M, n (%) 0.669
  M0 126 (69.6) 40 (66.7)
  M1 55 (30.4) 20 (33.3)
Complicated with bland thrombus, n (%) < 0.001*
  No 159 (87.8) 37 (61.7)
  Yes 22 (12.2) 23 (38.3)
Adrenalectomy, n (%) 0.011*
  No 92 (50.8) 15 (25.0)
  Yes 89 (49.2) 45 (75.0)
Segmental resection of IVC, n (%) 0.003*
  No 159 (87.8) 43 (71.7)
  Yes 22 (12.2) 17 (28.3)
Lymph node dissection, n (%) 0.248
  No 100 (55.2) 28 (46.7)
  Yes 81 (44.8) 32 (53.3)
Operation time/min, M (P25, P75) 289 (218, 374) 408 (342, 499) ＜0.001*
Blood loss/mL, M (P25, P75) 400 (150, 800) 3 000 (2 250, 4 000) ＜0.001*
Intraoperative infusion volume/mL, M (P25, P75) 0 (0, 400) 2 000 (1 300, 2 800) ＜0.001*
Pathological type, n (%) 0.854
  Clear cell carcinoma 148 (81.7) 52 (86.7)
  Papillary cell carcinoma 22 (12.2) 5 (8.3)
  Chromophobe cell carcinoma 2 (1.1) 0 (0)
  Unclassified cell carcinoma 7 (3.9) 3 (5.0)
  Xp11.2 cell carcinoma 2 (1.1) 0 (0)
Nuclear classification, n (%) 0.358
  1 3 (1.7) 0 (0)
  2 68 (37.5) 17 (28.3)
  3 74 (40.9) 26 (43.4)
  4 36 (19.9) 17 (28.3)
Sarcomatoid features, n (%) 0.128
  No 160 (88.4) 48 (80.0)
  Yes 21 (11.6) 12 (20.0)
Perirenal fat infiltration, n (%) 0.063
  No 129 (71.3) 35 (58.3)
  Yes 52 (28.7) 25 (41.7)
Postoperative hospital stay/d, M (P25, P75) 8 (6, 10) 12 (8, 15) ＜0.001*
     Serum creatinine after one week/(μmol/L),
M (P25, P75)		 98 (79.0, 115.5) 93 (80.0, 121.0) 0.799
Postoperative complications, n (%) ＜0.001*
  No 139 (76.8) 18 (30.0)
  Yes 42 (23.2) 42 (70.0)
Severe postoperative complications, n (%) 0.016*
  No 173 (95.6) 51 (85.0)
  Yes 8 (4.4) 9 (15.0)

Table 2

Logistic regressive analysis of univariate and multivariate of intraoperative massive haemorrhage"

Items Univariate Multivariate
OR (95%CI) P OR (95%CI) P
Gender
  Male Referent
  Female 0.756 (0.369-1.547) 0.443
Age 1.022 (0.993-1.052) 0.132
Clinical symptoms
  None Referent Referent
  Clinical symptoms 1.630 (0.715-3.716) 0.246 0.727
  Clinical symptoms 1.222 (0.33-4.527) 0.764 0.396
  Both 2.794 (1.087-7.181) 0.033* 0.276
BMI 1.050 (0.972-1.135) 0.212
Surgical approach
  Laparoscopic surgery Referent Referent
  Open surgery 9.365 (4.447-19.720) < 0.001* 6.730 (2.947-15.368) < 0.001*
Mayo classification
  0-2 Referent Referent
  3-4 5.527 (2.806-10.886) < 0.001* 2.294 (1.064-4.948) 0.034*
ASA grade
  1-2 Referent Referent
  3 2.842 (1.338-6.036) 0.007* 0.236
Preoperative serum creatinine 1.002 (0.998-1.005) 0.340
Preoperative hemoglobin 0.978 (0.965-0.991) 0.001* 0.105
Preoperative neutrophil 1.024 (0.976-1.075) 0.327
Preoperative lymphocyte 0.538 (0.282-1.026) 0.060
Preoperative monocyte 1.642 (0.381-7.080) 0.506
Preoperative platelet 0.996 (0.992-1.000) 0.037* 0.101
Lesion side
  Left Referent
  Right 0.861 (0.473-1.566) 0.861
Tumor diameter 1.047 (0.955-1.148) 0.328
Maximum tumor thrombus width 1.061 (1.033-1.091) < 0.001* 0.782
Clinical phase of M
  M0 Referent
  M1 1.145 (0.614-2.136) 0.669
Complicated with bland thrombus 4.493 (2.264-8.915) < 0.001* 3.236 (1.492-7.020) 0.003*
Adrenalectomy 3.101 (1.614-5.958) 0.001* 0.051
Segmental resection of IVC 2.857 (1.395-5.852) 0.004* 0.870
Lymph node dissection 1.411 (0.785-2.534) 0.249
1 Bahadoram S , Davoodi M , Hassanzadeh S , et al. Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatmen[J]. G Ital Nefrol, 2022, 39 (3): 1- 16.
2 Blute ML , Leibovich BC , Lohse CM , et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int, 2004, 94 (1): 33- 41.
doi: 10.1111/j.1464-410X.2004.04897.x
3 Reese AC , Whitson JM , Meng MV . Natural history of untreated renal cell carcinoma with venous tumor thrombus[J]. Urol Oncol, 2013, 31 (7): 1305- 1309.
doi: 10.1016/j.urolonc.2011.12.006
4 Yang L , Fu B . Nomograms for predicting overall survival and cancer-specific survival of patients with renal cell carcinoma and venous tumor thrombus: A population-based study[J]. Front Surg, 2022, 9, 929885.
doi: 10.3389/fsurg.2022.929885
5 Dufresne P , Moore L , Tardif PA , et al. Impact of trauma centre designation level on outcomes following hemorrhagic shock: A multicentre cohort study[J]. Can J Surg, 2017, 60 (1): 45- 52.
doi: 10.1503/cjs.009916
6 Zheng D , Pan H , Cui X , et al. Preliminary study on changes in coagulation function and component transfusion time in patients with massive hemorrhage[J]. Transfus Apher Sci, 2011, 44 (1): 15- 19.
doi: 10.1016/j.transci.2010.12.003
7 Liu Z , Zhao X , Zhang HX , et al. Peking University Third Hospital score: A comprehensive system to predict intra-operative blood loss in radical nephrectomy and thrombectomy[J]. Chin Med J (Engl), 2020, 133 (10): 1166- 1174.
doi: 10.1097/CM9.0000000000000799
8 中华医学会泌尿外科学分会中国肾癌联盟, 中国肾癌伴下腔静脉癌栓诊疗协作组. 肾癌伴静脉癌栓诊治专家共识[J]. 中华泌尿外科杂志, 2018, 39 (12): 881- 884.
9 刘茁, 马潞林, 田晓军, 等. 根治性肾切除术+下腔静脉癌栓取出术治疗Mayo 0~Ⅳ级下腔静脉癌栓的临床经验[J]. 中华泌尿外科杂志, 2017, 38 (11): 842- 847.
10 Beck AD . Renal cell carcinoma involving the inferior vena cava: Radiologic evaluation and surgical management[J]. J Urol, 1977, 118 (4): 533- 537.
doi: 10.1016/S0022-5347(17)58098-2
11 史沛清, 高治中. 肾癌并发肾静脉及下腔静脉瘤栓的诊断和治疗四例分析[J]. 中华肿瘤杂志, 1985, 7 (6): 425.
12 Fergany AF , Gill IS , Schweizer DK , et al. Laparoscopic radical nephrectomy with level Ⅱ vena caval thrombectomy: Survival porcine study[J]. J Urol, 2002, 168 (6): 2629- 2631.
doi: 10.1016/S0022-5347(05)64232-2
13 Romero FR , Muntener M , Bagga HS , et al. Pure laparoscopic radical nephrectomy with level Ⅱ vena caval thrombectomy[J]. Urology, 2006, 68 (5): 1112- 1124.
doi: 10.1016/j.urology.2006.08.1084
14 Xu B , Zhao Q , Jin J , et al. Laparoscopic versus open surgery for renal masses with infrahepatic tumor thrombus: The largest series of retroperitoneal experience from China[J]. J Endourol, 2014, 28 (2): 201- 207.
doi: 10.1089/end.2013.0519
15 Liu Z , Zhao X , Ge L , et al. Completely laparoscopic versus open radical nephrectomy and infrahepatic tumor thrombectomy: Comparison of surgical complexity and prognosis[J]. Asian J Surg, 2021, 44 (4): 641- 648.
doi: 10.1016/j.asjsur.2020.12.003
16 Abaza R . Initial series of robotic radical nephrectomy with vena caval tumor thrombectomy[J]. Eur Urol, 2011, 59 (4): 652- 656.
doi: 10.1016/j.eururo.2010.08.038
17 王林辉, 叶华茂, 吴震杰, 等. 中国首例达芬奇机器人辅助全腔镜下右肾癌根治切除联合腔静脉Ⅱ级癌栓取出术[J]. 第二军医大学学报, 2014, 35 (7): 763- 768.
18 Rose KM , Navaratnam AK , Faraj KS , et al. Comparison of open and robot assisted radical nephrectomy with level Ⅰ and Ⅱ inferior vena cava tumor thrombus: The Mayo Clinic experience[J]. Urology, 2020, 136, 152- 157.
doi: 10.1016/j.urology.2019.11.002
19 Liu Z , Zhu GD , Zhao X , et al. A modified surgical technique of shortening renal ischemia time in left renal cancer patients with Mayo level Ⅱ-Ⅳ tumor thrombus[J]. BMC Surg, 2020, 20 (1): 120.
doi: 10.1186/s12893-020-00769-w
20 Chopra S , Simone G , Metcalfe C , et al. Robot-assisted level Ⅱ-Ⅲ inferior vena cava tumor thrombectomy: Step-by-step technique and 1-year outcomes[J]. Eur Urol, 2017, 72 (2): 267- 274.
doi: 10.1016/j.eururo.2016.08.066
21 Wang B , Huang Q , Liu K , et al. Robot-assisted level Ⅲ-Ⅳ inferior vena cava thrombectomy: Initial series with step-by-step procedures and 1-year outcomes[J]. Eur Urol, 2020, 78 (1): 77- 86.
doi: 10.1016/j.eururo.2019.04.019
22 赵勋, 李丽伟, 马潞林, 等. 根治性肾切除术及下腔静脉癌栓取出术治疗Mayo Ⅳ级下腔静脉癌栓的手术技术及临床经验[J]. 现代泌尿外科杂志, 2019, 24 (8): 639- 644.
23 Wang GJ , Carpenter JP , Fairman RM , et al. Single-center experience of caval thrombectomy in patients with renal cell carcinoma with tumor thrombus extension into the inferior vena cava[J]. Vasc Endovascular Surg, 2008, 42 (4): 335- 340.
doi: 10.1177/1538574408320525
24 Shao P , Li J , Qin C , et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma[J]. Eur Urol, 2015, 68 (1): 115- 122.
doi: 10.1016/j.eururo.2014.12.011
25 Shen D , Wang H , Wang C , et al. Cumulative sum analysis of the operator learning curve for robot-assisted Mayo Clinic level Ⅰ-Ⅳ inferior vena cava thrombectomy associated with renal carcinoma: A Study of 120 cases at a single center[J]. Med Sci Monit, 2020, 26, e922987.
26 Quencer KB , Friedman T , Sheth R , et al. Tumor thrombus: Incidence, imaging, prognosis and treatment[J]. Cardiovasc Diagn Ther, 2017, 7 (Suppl 3): S165- S177.
27 Psutka SP , Boorjian SA , Thompson RH , et al. Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus[J]. BJU Int, 2015, 116 (3): 388- 396.
doi: 10.1111/bju.13005
28 李丽伟, 刘茁, 王淑敏, 等. 肾癌伴下腔静脉瘤栓合并血栓的多种影像学比较[J]. 北京大学学报(医学版), 2019, 51 (4): 678- 683.
29 Ayyathurai R , Garcia-Roig M , Gorin MA , et al. Bland thrombus association with tumour thrombus in renal cell carcinoma: Analysis of surgical significance and role of inferior vena caval interruption[J]. BJU Int, 2012, 110 (11 Pt B): 449- 455.
30 孟颖, 谭石, 王淑敏, 等. 超声及超声造影在肾细胞癌伴下腔静脉瘤栓合并血栓诊断中的价值[J]. 中华医学超声杂志(电子版), 2020, 17 (8): 728- 736.
31 Shirodkar SP , Ciancio G , Soloway MS . Vascular stapling of the inferior vena cava: Further refinement of techniques for the excision of extensive renal cell carcinoma with unresectable vena-caval involvement[J]. Urology, 2009, 74 (4): 846- 850.
doi: 10.1016/j.urology.2009.04.075
32 杜松良, 黄庆波, 张旭, 等. 下腔静脉瘤栓切除术中下腔静脉离断的术前决策及影响因素分析[J]. 微创泌尿外科杂志, 2018, 7 (4): 230- 234.
[1] Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639.
[2] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[3] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[4] Wanyin HOU,Jie DONG. Acquired cystic kidney hemorrhage in peritoneal dialysis patients: A report of three cases [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 546-550.
[5] Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331.
[6] Min FENG,Zhe CHEN,Yong-jing CHENG. A case of duodenal ulcer as prominent manifestation of IgG4-related disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1125-1129.
[7] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[8] Yun-yi XU,Zheng-zheng SU,Lin-mao ZHENG,Meng-ni ZHANG,Jun-ya TAN,Ya-lan YANG,Meng-xin ZHANG,Miao XU,Ni CHEN,Xue-qin CHEN,Qiao ZHOU. Read-through circular RNA rt-circ-HS promotes hypoxia inducible factor 1α expression and renal carcinoma cell proliferation, migration and invasiveness [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 217-227.
[9] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[10] Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155.
[11] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[12] Tian-yu CAI,Zhen-peng ZHU,Chun-ru XU,Xing JI,Tong-de LV,Zhen-ke GUO,Jian LIN. Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 628-635.
[13] Mei-ni ZUO,Yi-qing DU,Lu-ping YU,Xiang DAI,Tao XU. Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 636-643.
[14] Cai-peng QIN,Yu-xuan SONG,Meng-ting DING,Fei WANG,Jia-xing LIN,Wen-bo YANG,Yi-qing DU,Qing LI,Shi-jun LIU,Tao XU. Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 663-668.
[15] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd